Xarelto 10 26.51 mg FC tablets

Xarelto 10 26.51 mg FC tablets

S4
PDF Leaflet Revision Date: 12 May 2022

API: Monohydrate | Company: Bayer

Clinical Summary

Quick overview from the medicine insert

Indication

Prevention of VTE in major orthopedic surgery and treatment of DVT/PE.

Dosage (summary)

10 mg once daily for VTE prevention; 15 mg twice daily for DVT/PE treatment.

Special Populations

  • Elderly
  • Renal impairment
  • Hepatic impairment

Pregnancy & Breastfeeding

Contraindicated in pregnancy; use caution in breastfeeding.

Key Drug Interactions

  • Strong CYP3A4 inhibitors
  • Other anticoagulants
  • NSAIDs

Contraindications

  • Active bleeding
  • Severe hepatic disease
  • Hypersensitivity

Common side effects

  • Bleeding
  • Anaemia
  • Dizziness

Counselling Points

  • Monitor for signs of bleeding
  • Take with or without food
  • Do not double doses

Serious warnings

  • Increased risk of thrombotic events on discontinuation
  • Spinal/epidural hematoma risk
Important Disclaimer

The Xarelto 10 26.51 mg FC tablets professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites